Published in Annu Rev Pathol on October 17, 2011
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med (2015) 1.66
AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. Cell Stem Cell (2015) 1.51
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell (2017) 1.39
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem Soc Trans (2013) 1.30
NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov (2014) 1.27
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer (2015) 1.15
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A (2012) 1.14
Initiation of MLL-rearranged AML is dependent on C/EBPα. J Exp Med (2013) 1.13
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J (2013) 1.12
Septin functions in organ system physiology and pathology. Biol Chem (2014) 1.10
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget (2013) 1.06
Topoisomerase II and leukemia. Ann N Y Acad Sci (2014) 1.04
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene (2015) 0.99
Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem (2013) 0.99
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell (2014) 0.97
Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol (2015) 0.93
Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. PLoS One (2012) 0.92
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture. Front Oncol (2013) 0.91
Cyclin E deregulation promotes loss of specific genomic regions. Curr Biol (2015) 0.88
Chromatin-regulating proteins as targets for cancer therapy. J Radiat Res (2014) 0.88
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. J Clin Invest (2013) 0.87
Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics (2014) 0.86
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia (2012) 0.86
Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells. Nat Commun (2016) 0.85
Menin as a hub controlling mixed lineage leukemia. Bioessays (2012) 0.85
Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep (2015) 0.85
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells. Blood (2014) 0.84
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) (2012) 0.83
ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer Discov (2016) 0.82
Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. Genes Dev (2016) 0.82
Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 0.82
Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy (2013) 0.81
p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol (2013) 0.80
New and emerging factors in tumorigenesis: an overview. Cancer Manag Res (2015) 0.80
MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood (2013) 0.79
Discovery of MLL1 binding units, their localization to CpG Islands, and their potential function in mitotic chromatin. BMC Genomics (2013) 0.79
Epigenetic regulation of IL-12-dependent T cell proliferation. J Leukoc Biol (2015) 0.79
Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia (2015) 0.78
Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement. FASEB J (2014) 0.78
Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer (2015) 0.78
Caudal genes in blood development and leukemia. Ann N Y Acad Sci (2012) 0.77
WDR5 high expression and its effect on tumorigenesis in leukemia. Oncotarget (2016) 0.77
ELL inhibits E2F1 transcriptional activity by enhancing E2F1 deacetylation via recruitment of histone deacetylase 1. Mol Cell Biol (2013) 0.77
DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol (2013) 0.77
Trithorax and polycomb cooperation in MLL fusion acute leukemia. Haematologica (2013) 0.76
Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1α/CCL3. Leukemia (2016) 0.76
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett (2016) 0.76
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth. Nat Commun (2016) 0.76
MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment. Oncogene (2017) 0.76
PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Res (2016) 0.76
Zerovalent Fe, Co and Ni nanoparticle toxicity evaluated on SKOV-3 and U87 cell lines. J Appl Toxicol (2015) 0.76
Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia. Oncotarget (2016) 0.76
Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin. Oncotarget (2016) 0.75
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia (2016) 0.75
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr (2017) 0.75
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget (2016) 0.75
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther (2016) 0.75
Context matters in MLL-AF9-driven leukemias. Blood (2016) 0.75
Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes. J Biol Chem (2016) 0.75
Deregulation of HOX genes by DNMT3A and MLL mutations converges on BMI1. Leukemia (2016) 0.75
Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. J Autoimmun (2013) 0.75
NAD as a genotype-specific drug target. Chem Biol (2013) 0.75
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell (2017) 0.75
Setd1a and NURF mediate chromatin dynamics and gene regulation during erythroid lineage commitment and differentiation. Nucleic Acids Res (2016) 0.75
The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis. J Hematol Oncol (2017) 0.75
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet (2017) 0.75
Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res (2017) 0.75
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol (2017) 0.75
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet (2004) 11.31
RNA polymerase is poised for activation across the genome. Nat Genet (2007) 9.57
WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell (2005) 8.86
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature (2002) 7.54
The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell (2003) 7.47
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell (1992) 6.11
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell (1992) 5.39
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J (1998) 5.21
AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell (2010) 4.99
Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. J Biol Chem (2002) 4.75
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev (2003) 4.00
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell (2007) 3.59
Hox genes in hematopoiesis and leukemogenesis. Oncogene (2007) 3.55
Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol (2006) 3.54
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
An RNA polymerase II elongation factor encoded by the human ELL gene. Science (1996) 3.46
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet (1992) 3.43
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet (2006) 3.39
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell (2003) 3.35
Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet (1996) 3.32
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest (2006) 3.27
Eater, a transmembrane protein mediating phagocytosis of bacterial pathogens in Drosophila. Cell (2005) 3.22
The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B. J Biol Chem (2003) 3.08
The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol (2006) 3.03
MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med (2004) 2.97
Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol (1995) 2.89
Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J (2006) 2.89
Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell (2007) 2.82
11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A (1994) 2.67
Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol (2003) 2.66
MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci U S A (1998) 2.65
MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol (2001) 2.58
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell (2003) 2.54
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev (2010) 2.53
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell (2010) 2.50
The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol (1998) 2.48
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol (2009) 2.44
Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell (2010) 2.44
The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res (2002) 2.43
Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene (2001) 2.42
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
FLT3 as a therapeutic target in AML: still challenging after all these years. Blood (2010) 2.25
Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell (2007) 2.23
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood (2009) 2.19
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood (2009) 2.11
Defects in yolk sac hematopoiesis in Mll-null embryos. Blood (1997) 2.06
The Polycomb group--no longer an exclusive club? Curr Opin Genet Dev (2001) 2.05
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol (2009) 1.98
Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J (2000) 1.87
MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A (2003) 1.83
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell (2003) 1.79
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer (2010) 1.77
Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev (2007) 1.71
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene (2005) 1.64
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood (2010) 1.60
GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell (2010) 1.57
Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem (2010) 1.56
Regulation of Hox gene activity by transcriptional elongation in Drosophila. Curr Biol (2009) 1.55
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol (2010) 1.35
The "Atlas of genetics and cytogenetics in oncology and haematology" on the internet and a review on infant leukemias. Cancer Genet Cytogenet (2000) 1.34
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol (2009) 1.33
Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer (2003) 1.31
The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A (2005) 1.29
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature (2010) 1.29
Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood (2010) 1.29
Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest (2005) 1.26
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia (2010) 1.25
The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood (2008) 1.18
Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol (2010) 1.16
Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene (2008) 1.15
Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J (2000) 1.15
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood (2008) 1.12
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell (2010) 2.50
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood (2009) 1.90
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell (2003) 1.79
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A (2006) 1.67
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene (2005) 1.64
Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood (2011) 1.63
Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J Virol (2005) 1.46
The advent of targeted therapeutics and implications for pathologists. Am J Clin Pathol (2002) 1.38
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol (2010) 1.35
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol (2009) 1.33
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol (2007) 1.26
The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood (2008) 1.18
HOX proteins and leukemia. Int J Clin Exp Pathol (2008) 1.14
Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol Biol (2009) 1.13
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood (2004) 1.09
MLL core components give the green light to histone methylation. ACS Chem Biol (2006) 0.99
ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood (2011) 0.99
Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med (2010) 0.90
PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget (2010) 0.89
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity. J Biol Chem (2012) 0.89
MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep (2013) 0.86
Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. J Biol Chem (2013) 0.83
Epigenetic dysregulation in cancer. Am J Pathol (2009) 0.82
The role of menin in hematopoiesis. Adv Exp Med Biol (2009) 0.82
The Cancer Genome Anatomy Project: power tools for cancer biologists. Cancer Invest (2003) 0.80
MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood (2013) 0.79
Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias? Leuk Res (2010) 0.77
MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment? Cancer Cell (2008) 0.76
Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Curr Opin Hematol (2016) 0.76
Structural basis of multimer-mediated mayhem. Cancer Cell (2006) 0.75
Twenty-first century pathology sign-out. Clin Lab Med (2012) 0.75